-
Afghan govt says 'around 400' killed in Pakistani strike on Kabul rehab clinic
-
Russian ballet banned for 'gay propaganda' gets new life in Berlin
-
Malaysia hit with 3-0 forfeits to send Vietnam to Asian Cup
-
Rescue workers comb ruins of Kabul drug clinic after Pakistan strike
-
'Many dead': Wounded survivor escaped Kabul clinic strike
-
Belgian court decides on holding trial over 1961 Congo leader murder
-
Kabul drug rehab clinic in ruins after Pakistan strikes on Afghanistan
-
Israel strikes Tehran, Beirut as Iraq pulled deeper into Mideast war
-
Georgia ready for rugby elite despite rare Portugal defeat
-
Doncic leads Lakers to sixth straight win, Spurs sink Clippers
-
Iran 'negotiating' with FIFA over moving World Cup games to Mexico: embassy
-
Gavaskar condemns Indian-owned franchise for signing Pakistan bowler
-
Cash handouts, fare hikes as Philippines battles soaring fuel costs
-
Alleged Bondi Beach killer's mother received death threats, court told
-
Venezuela end Italy fairytale to reach World Baseball Classic final
-
Sweden's prisons prepare to house young teens
-
Indonesia weighs response to price pressures from Middle East war
-
In Hollywood, AI's no match for creativity, say top executives
-
Sao Paulo AI policing nabs criminals, and a few innocents
-
Trump faces coalition of the unwilling on Iran
-
Nvidia chief expects revenue of $1 trillion through 2027
-
Nvidia making AI module for outer space
-
Migrant workers bear brunt of Iran attacks in Gulf
-
From Bedroom Startup to Multi-State Firm: Razavi Law Group Founder Ali Razavi Inspires Future Lawyers at UCLA
-
Gold IRA Rollover: Learn to Transfer Gold IRA Guide Released (2026)
-
EQS Group Launches Analytics Module in the Compliance COCKPIT to Turn Compliance Data into Actionable Intelligence
-
Nano One Advances Candiac LFP Production Capacity Expansion Project, Detailed Engineering & Equipment Procurement
-
Empire Metals Limited Announces Diamond Drilling Results
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - March 17
-
Star Copper Reports First Phase 2 Drill Results Extending Mineralization to West, North and South
-
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
-
Former tennis world number 39 banned for doping
-
Kennedy Center board approves 2-year closure for renovation
-
US judge halts implementation of Trump vaccine overhaul
-
Afghanistan accuses Pakistan of deadly airstrike on drug rehab centre in Kabul
-
Iran footballers train with Australia club and say 'everything will be fine'
-
Trump asks China to delay Xi summit as Iran war rages
-
Multiple suicide bombers hit Nigeria's Maiduguri city after years of calm
-
Wolves fightback frustrates Brentford
-
Trump vows to 'take' Cuba as island reels from oil embargo
-
Israel president tells AFP Europe should back efforts to 'eradicate' Hezbollah
-
Equities rise on oil easing, with focus on Iran war and central banks
-
Mbappe set for Real Madrid return against Man City
-
Nvidia rides 'claw' craze with AI agent platform
-
Alleged narco trafficker makes first US court appearance
-
Neymar misses out as Endrick returns to Brazil squad
-
South Lebanon's Christian towns insist they are not part of Israel-Hezbollah war
-
Alleged narco trafficker Marset makes first US court appearance
-
Securing the Strait of Hormuz: Tactics and threats
-
Cuba hit by total blackout as US fuel blockade bites
CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth
SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in proven, science-backed natural ingredients and products, today announced that it has modified its existing outstanding notes to include a conversion feature pursuant to which the outstanding balance of the notes may be converted into common shares of the Company at a fixed conversion price of $0.06 per share.
"We are pleased with the successful completion of a comprehensive debt restructuring, marking a significant milestone in the Company's strategic plan to enhance financial flexibility and accelerate long-term growth," said Joseph Dowling, CEO of CV Sciences. "This is a transformative step for our Company in strengthening our balance sheet and positioning the Company for sustained profitability. This transaction better equips us to deliver value to our customers, partners and shareholders, while pursuing new opportunities with confidence."
CV Sciences has recently launched Empowr, a plant-based protein and creatine formula designed for total wellness. With this launch, CV Sciences has continued to expand its growing portfolio of innovative wellness solutions under its +PlusHLTH™, Happy Living Through Health, cannabinoid-free supplement line. Rooted in rigorous science and fortified by clinically proven wellness ingredients, the +PlusHLTH line delivers targeted formulations for optimized health, improved performance, and increased vitality. For more information, please visit https://www.pluscbdoil.com/plushlth.html or https://www.cvsciences.com/.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces cannabinoid-free supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ subsidiary specializes in contract manufacturing and branded products for the nutraceutical and plant-based food industries, with distribution primarily across the EU and select international markets. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
Forward Looking Statements
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties.
Contact Information
[email protected]
SOURCE: CV Sciences, Inc.
View the original press release on ACCESS Newswire
S.Gregor--AMWN